Evidence map›Paper›PMID 23236415›Full record

ArticlePloS one2012

Targeting fatty acid binding protein (FABP) anandamide transporters - a novel strategy for development of anti-inflammatory and anti-nociceptive drugs.

William T Berger, Brian P Ralph, Martin Kaczocha, Jing Sun, Trent E Balius, Robert C Rizzo, Samir Haj-Dahmane, Iwao Ojima, Dale G Deutsch

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 94 papers.

0numbers the graph read from it
0cells of the map it votes in
94citing papers in PubMed
7.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

94 citing papers in PubMed, 156 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. DOCKweb: a web-based GUI platform for molecular modeling with DOCK6.Journal of computer-aided molecular design · 2026
    Article
  5. Article
  6. Review
  7. Evaluating FABP5 as a Therapeutic Target for Pain Management.European journal of pain (London, England) · 2026
    Review
  8. Chemical Probes for Investigating the Endocannabinoid System.Current topics in behavioral neurosciences · 2026
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

34 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

William T BergerChemistry and the Institute of Chemical Biology and Drug Discovery, Stony Brook University, Stony Brook, New York, USA.
Brian P Ralph
Martin Kaczocha
Jing Sun
Trent E Balius
Robert C Rizzo
Samir Haj-Dahmane
Iwao Ojima
Dale G Deutsch
Stony Brook University · USApplied Mathematics (United States) · USUniversity at Buffalo, State University of New York · US

Funding

FABPs Mediate Activation of PPAR Alpha Receptors by N-AcylethanolaminesR21DA032232 · NIDA · STATE UNIVERSITY NEW YORK STONY BROOK · PI KACZOCHA, MARTIN · 2011 to 2012
$389k
NIDA NIH HHS DA01641904NIDA NIH HHS DA02695301NIDA NIH HHS DA032232NIDA NIH HHS R21 DA032232
6 · The paper itself

Abstract

Fatty acid binding proteins (FABPs), in particular FABP5 and FABP7, have recently been identified by us as intracellular transporters for the endocannabinoid anandamide (AEA). Furthermore, animal studies by others have shown that elevated levels of endocannabinoids resulted in beneficial pharmacological effects on stress, pain and inflammation and also ameliorate the effects of drug withdrawal. Based on these observations, we hypothesized that FABP5 and FABP7 would provide excellent pharmacological targets. Thus, we performed a virtual screening of over one million compounds using DOCK and employed a novel footprint similarity scoring function to identify lead compounds with binding profiles similar to oleic acid, a natural FABP substrate. Forty-eight compounds were purchased based on their footprint similarity scores (FPS) and assayed for biological activity against purified human FABP5 employing a fluorescent displacement-binding assay. Four compounds were found to exhibit approximately 50% inhibition or greater at 10 µM, as good as or better inhibitors of FABP5 than BMS309403, a commercially available inhibitor. The most potent inhibitor, γ-truxillic acid 1-naphthyl ester (ChemDiv 8009-2334), was determined to have K(i) value of 1.19±0.01 µM. Accordingly a novel α-truxillic acid 1-naphthyl mono-ester (SB-FI-26) was synthesized and assayed for its inhibitory activity against FABP5, wherein SB-FI-26 exhibited strong binding (K(i) 0.93±0.08 µM). Additionally, we found SB-FI-26 to act as a potent anti-nociceptive agent with mild anti-inflammatory activity in mice, which strongly supports our hypothesis that the inhibition of FABPs and subsequent elevation of anandamide is a promising new approach to drug discovery. Truxillic acids and their derivatives were also shown by others to have anti-inflammatory and anti-nociceptive effects in mice and to be the active component of Chinese a herbal medicine (Incarvillea sinensis) used to treat rheumatism and pain in humans. Our results provide a likely mechanism by which these compounds exert their effects.

Indexed as

AnalgesicsAnimalsAnti-Inflammatory AgentsArachidonic AcidsBiological TransportCarrier ProteinsDrug DiscoveryEndocannabinoidsFatty Acid-Binding Protein 7Fatty Acid-Binding ProteinsHumansMicePolyunsaturated AlkamidesTumor Suppressor ProteinsAnalgesicsanandamideAnti-Inflammatory AgentsArachidonic AcidsCarrier ProteinsEndocannabinoidsFABP5 protein, humanFABP7 protein, humanFatty Acid-Binding Protein 7Fatty Acid-Binding ProteinsPolyunsaturated AlkamidesTumor Suppressor Proteins

Identifiers

PMID23236415
PMCPMC3517626
OpenAlexW2013276134

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.